Clinical Trial Search

Primary: Period 1: Area Under the Plasma Concentration-time Curve From Time 0 to the End of the Dosing Interval at Steady State (AUC [0-tau]) of EE — 748.7 Hour*picograms per…

Primary: Part A: Cmax: Maximum Observed Plasma Concentration for Ixazomib — 89.06 nanogram per milliliter (ng/mL)

Primary: Groups A, C and D; Cmax: Maximum Observed Plasma Concentration for TAK-954 (Total and Free) — 2.623; 2.536; 2.660; 0.1270 nanogram per milliliter (ng/mL) — p=0.7265

Primary: Number of Participants With Abemaciclib Dose-Limiting Toxicity (DLT) — 0; 0; 1 Participants

Primary: Area Under Plasma Concentration-time Curve From Zero to Infinity (AUC) — 171.3; 167.5; 87.14; 149.0 ng*h/mL

Primary: Treatment B vs Treatment A (Part 1), Combined Molar Exposure for Cmax: Maximum Observed Plasma Concentration of TAK-788, AP32960, and AP32914 — 13.7; 39.2 nM

Primary: Percentage of Participants Experiencing Treatment Emergent Adverse Events — 25.0; 14.3; 16.7; 13.3 percentage of participants

Primary: Number of Patients With Dose-Limiting Toxicities Adverse Events (DLTs) — 0; 0; 0; 0 Participants

Primary: Relative Bioavailability (Frel) of a Capsule Compared to a Liquid Formulation of IX-01 While Fasting, as Calculated by a Ratio of Area Under the Plasma Concentration…

Primary: Number of Participants With Serious and Non-serious Adverse Events — 3; 3; 3; 5 Participants

Primary: Cmax — 40.866; 42.843; 39.382 ng/mL

Primary: Best Response Following Extended Use of CS-7017 Upon Completion of Participation in a Clinical Study of CS-7017 in Participants With Cancer — 0; 1; 1; 0 Participants

Primary: Percentage of Participants Experiencing Treatment-Emergent Adverse Events — 75.0; 33.3 percentage of participants

Primary: Maximum Tolerated Dose (MTD) or Biologically Active Dose of Cirmtuzumab — 20 mg/kg

Primary: Overall Response Rate — 5 participants